

Monika GawaÅ,ko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9393113/publications.pdf>

Version: 2024-02-01

68
papers

753
citations

687363

13
h-index

610901

24
g-index

69
all docs

69
docs citations

69
times ranked

775
citing authors

#	ARTICLE	IF	CITATIONS
1	Adiposity-associated atrial fibrillation: molecular determinants, mechanisms, and clinical significance. <i>Cardiovascular Research</i> , 2023, 119, 614-630.	3.8	15
2	A VIRTUAL Sleep Apnoea management pathway For the work-up of Atrial fibrillation patients in a digital Remote Infrastructure: VIRTUAL-SAFARI. <i>Europace</i> , 2022, 24, 565-575.	1.7	23
3	A systematic review of mobile health opportunities for atrial fibrillation detection and management. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e205-e208.	1.8	3
4	Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. <i>Cardiovascular Research</i> , 2022, 118, 2415-2427.	3.8	45
5	Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease. <i>Cardiology Journal</i> , 2022, 29, 205-215.	1.2	7
6	Success rate and safety of catheter ablation in preexcitation syndrome: A comparison between adult and pediatric patients. <i>Cardiology Journal</i> , 2022, 29, 88-92.	1.2	2
7	Fat chance for POAF? Pericardial adipose tissue and the arrhythmogenic substrate for postoperative atrial fibrillation. <i>IJC Heart and Vasculature</i> , 2022, 39, 101000.	1.1	0
8	Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 2705.	2.4	7
9	Association of Hyperuricemia with Impaired Left Ventricular Systolic Function in Patients with Atrial Fibrillation and Preserved Kidney Function: Analysis of the POL-AF Registry Cohort. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7288.	2.6	2
10	Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORPâ€AF General Longâ€Term Registry. <i>International Journal of Clinical Practice</i> , 2021, 75, e13701.	1.7	3
11	Implementation of an on-demand app-based heart rate and rhythm monitoring infrastructure for the management of atrial fibrillation through teleconsultation: TeleCheck-AF. <i>Europace</i> , 2021, 23, 345-352.	1.7	65
12	Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, including compliance with current guidelinesâ€”data from the POLish Atrial Fibrillation (POL-AF) Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 14-27.	1.7	8
13	Surgery-related cardiac stress: A susceptibility test of late atrial fibrillation recurrence?. <i>IJC Heart and Vasculature</i> , 2021, 32, 100693.	1.1	1
14	Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 1341.	2.4	2
15	Symptomatic and Asymptomatic Patients in the Polish Atrial Fibrillation (POL-AF) Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 1091.	2.4	7
16	Risk of left atrial appendage thrombus in older patients with atrial fibrillation. <i>Archives of Medical Science</i> , 2021, , .	0.9	3
17	Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 1780.	2.4	2
18	Long-term intermittent versus short continuous heart rhythm monitoring for the detection of atrial fibrillation recurrences after catheter ablation. <i>International Journal of Cardiology</i> , 2021, 329, 105-112.	1.7	24

#	ARTICLE	IF	CITATIONS
19	The European TeleCheck-AF project on remote app-based management of atrial fibrillation during the COVID-19 pandemic: centre and patient experiences. <i>Europace</i> , 2021, 23, 1003-1015.	1.7	56
20	Hyperuricemia as a Marker of Reduced Left Ventricular Ejection Fraction in Patients with Atrial Fibrillation: Results of the POL-AF Registry Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1829.	2.4	6
21	Pericardial adipose tissue: An emerging biomarker of atrial fibrillation?. <i>International Journal of Cardiology</i> , 2021, 331, 122-123.	1.7	0
22	The photoplethysmography dictionary: practical guidance on signal interpretation and clinical scenarios from TeleCheck-AF. <i>European Heart Journal Digital Health</i> , 2021, 2, 363-373.	1.7	22
23	Gut-microbiota derived TMAO: A risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation?. <i>IJC Heart and Vasculature</i> , 2021, 34, 100818.	1.1	2
24	Oral anticoagulation and therapy of atrial flutter: discontinuation of anticoagulation revisited. <i>International Journal of Cardiology</i> , 2021, 333, 117-118.	1.7	1
25	Does gut microbiota affect atrial rhythm? Causalities and speculations. <i>European Heart Journal</i> , 2021, 42, 3521-3525.	2.2	23
26	The role of hemostatic markers as venous stenosis or occlusion predictors following first transvenous cardiac device implantation. <i>Cardiology Journal</i> , 2021, 28, 690-696.	1.2	1
27	Radiation Safety and Electrophysiologists: Radiation Protection Status “Go for Zero Fluoroscopy European Heart Rhythm Association Registry. <i>Cardiology</i> , 2021, 146, 600-606.	1.4	1
28	On-Demand Mobile Health Infrastructure for Remote Rhythm Monitoring within a Wait-and-See Strategy for Recent-Onset Atrial Fibrillation: TeleWAS-AF. <i>Cardiology</i> , 2021, 146, 392-396.	1.4	14
29	Why Did All Patients with Atrial Fibrillation and High Risk of Stroke Not Receive Oral Anticoagulants? Results of the Polish Atrial Fibrillation (POL-AF) Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 4611.	2.4	1
30	Self-Reported Mobile Health-Based Risk Factor and CHA2DS2-VASc-Score Assessment in Patients With Atrial Fibrillation: TeleCheck-AF Results. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 757587.	2.4	5
31	Direct oral anticoagulation and severe obesity “One size fits all?. <i>IJC Heart and Vasculature</i> , 2021, 37, 100923.	1.1	3
32	The quality of life in patients with at least moderate ischemic mitral regurgitation qualified to cardiosurgery treatment. <i>Folia Medica Cracoviensia</i> , 2021, 61, 65-83.	0.3	0
33	Prevalence and risk factors of left atrial thrombus in patients with atrial fibrillation and lower class (IIa) recommendation to anticoagulants. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 717-724.	1.7	5
34	COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. <i>IJC Heart and Vasculature</i> , 2020, 30, 100631.	1.1	104
35	The gut microbial-derived metabolite trimethylamine N-oxide: A missing link between lifestyle-components and atrial fibrillation?. <i>IJC Heart and Vasculature</i> , 2020, 29, 100581.	1.1	1
36	Decreased left atrial appendage emptying velocity as a link between atrial fibrillation type, heart failure and older age and the risk of left atrial thrombus in atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2020, 74, e13609.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 3565.	2.4	5
38	Inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut: A new antihypertensive concept. <i>IJC Heart and Vasculature</i> , 2020, 29, 100591.	1.1	9
39	Management of cardiac arrhythmias in patients with autoimmune disease—Insights from EHRA Young Electrophysiologists. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1194-1198.	1.2	1
40	Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-10.	1.1	0
41	Remote management and education in patients with cardiovascular conditions during COVID-19 and beyond. <i>IJC Heart and Vasculature</i> , 2020, 30, 100646.	1.1	4
42	On-demand mobile health infrastructures to allow comprehensive remote atrial fibrillation and risk factor management through teleconsultation. <i>Clinical Cardiology</i> , 2020, 43, 1232-1239.	1.8	36
43	A call for a more objective and longitudinal reporting of lifestyle components in cardiovascular research. <i>IJC Heart and Vasculature</i> , 2020, 27, 100506.	1.1	2
44	Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-7.	2.5	17
45	Thrombus in the left atrial appendage in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants in clinical practice—A multicenter registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2005-2012.	1.7	4
46	Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?. <i>Medicine (United States)</i> , 2020, 99, e20570.	1.0	3
47	Cardiac Arrhythmias in Autoimmune Diseases. <i>Circulation Journal</i> , 2020, 84, 685-694.	1.6	50
48	Electrophysiological Procedures in Patients With Coagulation Disorders—A Systemic Review. <i>Circulation Journal</i> , 2020, 84, 875-882.	1.6	0
49	Implantation of the Micra transcatheter pacing system: Single Polish center experience with the real costs of hospitalization analysis. <i>Cardiology Journal</i> , 2020, 27, 47-53.	1.2	6
50	Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial. <i>Cardiology Journal</i> , 2020, 26, 661-668.	1.2	9
51	Trends in antithrombotic management in patients with atrial fibrillation: a report from Polish participants in the EURObservational Research Programme “Atrial Fibrillation General Long-Term Registry. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 196-205.	0.4	5
52	Left Ventricular Outflow Tract Obstruction Due to Elongation of Anterior Mitral Leaflet. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009524.	2.6	0
53	Paradoxical low-flow aortic stenosis—baseline characteristics, impact on mortality. <i>Postępy W Kardiologii Interwencyjnej</i> , 2019, 15, 13-19.	0.2	1
54	Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus. <i>Heart</i> , 2019, 105, 1310-1315.	2.9	56

#	ARTICLE	IF	CITATIONS
55	Predictors of venous stenosis or occlusion following first transvenous cardiac device implantation: Prospective observational study. <i>Journal of Vascular Access</i> , 2019, 20, 495-500.	0.9	10
56	Endovascular extraction of entrapped long-term central feeding catheter: Case series. <i>Journal of Vascular Access</i> , 2019, 20, 329-332.	0.9	1
57	Initial experience with the subcutaneous implantable cardioverter-defibrillator with the real costs of hospitalization analysis in a single Polish center. <i>Cardiology Journal</i> , 2019, 26, 360-367.	1.2	4
58	The rationale and design of the LATTEE registry – the first multicenter project on the Scientific Platform of the “Club 30” of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2019, 77, 1078-1080.	0.6	7
59	Novel biochemical predictors of unfavorable prognosis for stable coronary disease. <i>Medicine (United States)</i> , 2018, 97, e13074.	1.0	10
60	Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study. <i>Medicine (United States)</i> , 2018, 97, e13074.	1.0	10
61	Perioperative risk assessment with Euroscore and Euroscore II in patients with coronary artery or valvular disease. <i>Medicine (United States)</i> , 2018, 97, e13572.	1.0	6
62	An interactive assistant for patients with cardiac implantable electronic devices. <i>Medicine (United States)</i> , 2018, 97, e13572.	1.0	6
63	Long-term prognosis following acute coronary syndromes: a prospective observational study of an unselected group treated in the 24/7 cardiac catheterisation laboratory at a university hospital. <i>Kardiologia Polska</i> , 2018, 76, 755-763.	0.6	2
64	Initial experience of catheter ablation for cardiac arrhythmias in children and adolescents at a newly built ablation centre. <i>Kardiologia Polska</i> , 2018, 76, 130-135.	0.6	2
65	Risk factors for adverse outcomes of patients with acute coronary syndrome: single-centre experience with long-term follow-up of treated patients. <i>Kardiologia Polska</i> , 2018, 76, 881-888.	0.6	4
66	Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 823-831.	0.4	13
67	Three-dimensional print facilitated ventricular tachycardia ablation in patient with corrected congenital heart disease. <i>Cardiology Journal</i> , 2017, 24, 584-585.	1.2	4
68	Ventricular tachycardia successfully treated with wearable cardioverter-defibrillator. <i>Kardiologia Polska</i> , 2017, 75, 1355-1355.	0.6	0